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Introduction
Patients suffering from multiple myeloma treated with
Melphalan in a standard dose and Prednizone, survive, on
average, no more than four years [1]. 3% of the patients
survive ten years, whereas complete remission has not
been observed [2, 3]. The introduction of multi-drug che-
motherapy has not improved the above figures [4]. Higher
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I n t r o d u c t i o n.  Patients suffering from multiple myeloma treated with melphalan and prednizone survive three years on ave-
rage. Recently a higher survival rate has been associated with high-dose chemotherapy followed by transplantation of haema-
topoietic progenitor cells. This paper presents our experience with high-dose chemotherapy in the treatment of patients suffe-
ring from multiple myeloma.
Pa t i e n t s  a n d  m e t h o d s.  31 patients with multiple myeloma were treated with autologous transplantation of progenitor
cells from peripheral blood: 24 patients underwent a single transplantation, whereas 7 underwent double transplantation. Du-
ring conditioning regimen melphalan was administered for the first transplantation, and melphalan or BEAM regimen for the
second one.
Re s u l t s.  29 patients achieved complete haematological recovery, the regeneration of megakaryopoiesis being statistically de-
layed after the second transplantation. There were 12 CR, 2 PR and 15 NR. Three year EFS was 31%, OS was 85%. The risk
factor for EFS was late versus early transplant, and for OS it was renal failure.
C o n c l u s i o n s.  Results show that high-dose chemotherapy, followed by autologous transplantation of progenitor cells, is a re-
latively low risk procedure (4%). and allows achieving long term remission.
Leczenie szpiczaka mnogiego za pomocà wysoko dawkowanej chemioterapii
oraz autologicznego przeszczepu szpiku – doÊwiadczenia w∏asne
W s t ´ p.  Pacjenci chorujàcy na szpiczaka mnogiego, leczeni przy pomocy melfalanu w konwencjonalnych dawkach w skoja-
rzeniu z prednizonem, prze˝ywajà Êrednio trzy lata. Wyd∏u˝enie d∏ugoÊci ˝ycia mo˝na uzyskaç poprzez zastosowanie chemio-
terapii w wysokich dawkach, skojarzonej z autologicznym przeszczepem szpiku. Prezentowana praca przedstawia w∏asne do-
Êwiadczenia, zwiàzane ze stosowaniem wysoko dawkowanej chemioterapii w leczeniu chorych ze szpiczakiem mnogim.
Pa c j e n c i  i m e t o d y.  31 chorych zosta∏o poddanych przeszczepowi z krwi obwodowej: 24 z nich otrzyma∏o przeszczep po-
jedynczy, u siedmiu zastosowano podwójny zabieg. W kondycjonowaniu do pierwszego przeszczepu stosowano melfalan, do
drugiego melfalan lub BEAM.
W y n i k i.  U 29 chorych dosz∏o do pe∏nej regeneracji szpiku, po drugim z zabiegów obserwowano przed∏u˝ony czas odtwarza-
nia si´ megakariopoezy. Szacowane 3-letnie prze˝ycie bez choroby wynosi 31%, ca∏kowite prze˝ycie 85%. Wykonanie przeszcze-
pu w póênym okresie choroby stanowi czynnik ryzyka jej nawrotu, czynnikiem ryzyka dla ca∏kowitego prze˝ycia jest niewydol-
noÊç nerek w chwili przeszczepu.
W n i o s k i.  Uzyskane rezultaty sugerujà, ˝e wysoko dawkowana chemioterapia, po∏àczona z autologicznym przeszczepem szpi-
ku, jest stosunkowo bezpiecznà procedurà i pozwala na uzyskanie d∏ugotrwa∏ych remisji.
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expectations concerning the survival rate have recently
been associated with high-dose chemotherapy followed by
transplantation of haematopoietic progenitor stem cells
(HDC/HSCT). In a randomised clinical trial conducted in
France (IFM 90), on a group of patients who underwent
autologous transplantation, prolonged event free survival
(EFS) and overall survival (OS) were observed [5]. The
introduction of high-dose chemotherapy was also demon-
strated in a case-matched study conducted by Southwest
Oncology Group and a in a population-base study prefor-
med by Nordic Myeloma Study Group [6, 7]. The results
of the above investigations have prompted the European
Bone Marrow Transplant registry (EBMT) to recommend
autologous transplantations of progenitor cells to be routi-
nely employed in clinical practice [8]. This paper pre-
sents our experience concerned with the employment of
HDC/HSCT in treatment of patients with multiple myelo-
ma.
Patients and methods
Since 1996 31 patients with myeloma underwent HDC/HSCT at
the Department of Haematology of the Medical University of
Gdaƒsk. The characteristics of patients at the first and second
transplant are detailed in Tables I and II. Only patients respon-
ding to previous treatment, with ≤30% plasmocytes in bone
marrow were qualified for the HDC/HSCT.
In order to achieve mobilisation of progenitor stem cells,
a cycle of Cyclophosphamide was administered once at a dose of
6 g/m2 (31 transplantations), 4 g/m2 (two transplantations) or 3
g/m2 (5 transplantations). Beginning with the next day rhG-CSF
(Neupogen, Roche Polska) was administered subcutaneously
on a daily basis. G-CSF was administered at a dose of 300 µg in
patients weighing less than 60 kg, and, 480 µg in the remaining.
Progenitor stem cells were collected at the growth stage of leuko-
cytosis, following a nadir induced by the employment of the
above presented chemotherapy, on exceeding a level of 1,0 G/l.
During conditioning regimen Melphalan was administered at
a dose of 200 mg/m2 (day -2), followed by an autologous trans-
plantation of progenitor cells (details in Table III). In seven ca-
ses the procedure was repeated (Table II).
Conditioning regimen preceding the second transplanta-
tion depended on the effects achieved during the first one. In
the event of complete or partial remission Melphalan was ad-
ministered again in the initial dose. If no effect was achie-
ved the BEAM (BCNU 300 mg/m2, Etoposide 150 mg/m2,
ARA-C 200 mg/m2, Melphalan 140 mg/m2) regimen was introdu-
ced (Table III). Complete remission was defined according to
Blade et al [9] as the lack of monoclonal protein in serum and
urine in immunoelectrophoresis and immunofixation studies,
and a percentage count of plasmocytes in bone marrow lower
than 5%. Partial remission was defined as the normalisation of
the total percentage of plasmocytes in bone marrow (<5%),
and a reduction of the amount of monoclonal protein by 50% or
to a value of 0.2g/l in 24-hour urine in the case of Bence-Jones
disease. In the period following transplantation antibacterial
(fluorochinolones), antimycotic (fluconazole) and antiviral
(Acyclovir used up to day +30) prophylaxis were introduced.
At a later stage antibacterial prophylaxis was discontinued, the
administration of Acyclovir was extended to day +100, and the
administration of anti-HBS serum (Hepatect) was employed
due to a high risk of hepatitis type B. Routinely, following trans-
plantation, haematopoietic growth factors were not administe-
red. In six patients Interferon alpha, was administered at a dose
of 3 mln. UI three times a week, from the time of the completion
of the grafting criteria until one year after transplantation. In the
second half of 1997 the above procedure was discontinued; sup-
portive therapy following transplantation not being employed.
S t a t i s t i c a l  m e t h o d s
Survival probabilities were calculated employing the Ka-
plan-Meier method and comparisons made using the log-rank
test. The following variables were included in a model of progno-
stic factors for OS and EFS: Sex, number of transplants, heavy
and light chain type, stage according to the Durie-Salmon classi-
fication, time of transplant (early/late), renal sufficiency, β2-mi-
croglobulin level >6.0 mg/ml. When comparing the rate of ha-
ematological recovery after every transplantation, the Wilco-
xon test was utilised.
Results
From among 31 patients who underwent transplantation
of hematopoietic progenitor cells, 29 achieved complete
haematological recovery. One patient, treated during
a period of renal insufficiency, with a creatinine level of
Table I. Characteristics of patients at the first transplant
No. of No (%)
evaluated 
patients
Myeloma type: 31
IgG 21 (68)
Bence-Jones 6 (19)
IgA 2 (6)
IgD 1 (3)
Non-secreting 1 (3)
Light chain type: 31
Kappa 23 (74)
Lambda 7 (23)
Non-secreting 1 (3)
Sex: 31
females 16 (52)
males 15 (48)
Disease stage at diagnosis 31
(Durie-Salmon): 
I 4 (13)
II 4 (13)
III 23 (75)
Renal function: 31
A 27 (87)
B 4 (13)
Number of previous chemotherapy regimens: 31
1 14 (58)
2 3 (13)
3-4 5 (21)
6-7 2 (8)
median 1
range 1-7
β2-mikroglobulin level: 30
<6/.0 24 (80)
≥6.0 6 (20)
Indications for transplant: 31
early transplant 21 (68)
late transplant 10 (32)
Type of transplant 31
single 24 (77)
double 7 (23)
Age of patients 49 (34-66)
(median, range)
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>5mg/dl, died due to septic complications. In another
patient reconstitution of megakaryopoiesis was not achie-
ved in a period of two years following the second trans-
plantation. The patient has symptoms of active myeloma
and is at present treated with Thalidomide. Among other
observed complications oral mucositis and neutropenic fe-
ver were most often, usually mild or moderate.
In the majority of patients the process of recovery of
haematopoiesis was satisfactory. The level of leukocytes
exceeded the value of 1.0 G/l usually on day 15 (11-24)
following the first transplantation, and on day 19 (13-29)
after the second one. Granulocytes achieved a level of
0.5 G/l on day 17 (10-28) following the first transplanta-
tion, and on day 20 (13-29) after the second one. The ra-
te of recovery of leukocytes and granulocytes after the
first and second transplantations did not differ signifi-
cantly. Platelets presented a value higher than 50 G/l on
day 21 (10-32) after the first transplantation, and on day
38 (18-53) after the second one, the difference being sta-
tistically significant (p=0.04) (Table III).
As a result of the transplants 12 patients achieved
complete (CR) and 2 partial remission (PR), according to
the criteria presented in the Patients and Methods sec-
tion. In the remaining 16 patients the reduction of monoc-
lonal protein was less than 50% or the count of plasmocy-
tes following treatment exceeded 5%. Presently, at a me-
dian time of observation of +643 days, 26 of the 31
patients, who underwent transplantation are alive, 7 of
them still in CR. The three year OS is 85% (Figure 1),
and the three year EFS is 31% (Figure 2). The only risk
Table II. Characteristic of patients at the second transplant
No. of No / %
evaluated 
patients
Myeloma type: 7
IgG 4 (57)
Bence-Jones 3 (43)
Light chain type: 7
Kappa 2 (28)
Lambda 5 (71)
Sex: 7
females 4 (57)
males 3 (43)
Disease stage at diagnosis (Durie-Salmon): 7
II 1 (14)
III 6 (86)
Renal function 7
A 7 (100)
B 0  (0)
Indications for transplant: 7
early transplant 6 (86)
late transplant 1 (14)
Age of patients: 7 44
median, range (36-50)
Time between the first and the second transplant: 7 179
median, range (days) (134-242)
Table III. Characteristics of the transplants
First Second 
transplant transplant
Conditioning regimen:
Melphalan 200 31 (100%) 5 (71%)
BEAM 2 (29%)
(No, %)
Characteristics of transplanted material:
MNC (x108) 4.8 (1.7–10.2) 4.4 (1.9–6.4)
CD34 (x106) 6.4 (1.2–93.2) 2.1 (0.6–6.1)
CFU-GM (x104) 39.2 (12.6–192.2) 23.8 (7.1–82.1)
(median, range)
Regeneration time:
leukocyte >1.0 G/l 15 (11–24) 19 (13–29)
granulocyte >0.5 G/l 17 (10–28) 20 (13–29)
platelets > 50 G/l 21 (10–NR) 38 (18–NR)
(median, range)
Results:
CR 8 (33%) 4 (57%)
PR 1 (4%) 1 (14%)
<PR 14 (58%) 2 (29%)
toxic death 1 (4%) 0
(No, %)
Figure 1. Platelet regeneration after each transplant
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factor for OS was renal insufficiency (p>0.01) (Figure
4), and for EFS the time of transplant (early versus late)
(p=0.015).
Discussion
Multiple myeloma is the second most common indica-
tion for conducting autologous transplantations of bone
marrow in Europe, following non-Hodgkin lymphoma
according to the European Bone Marrow Transplanta-
tion Registry (EBMT) [8]. Administration of autologous
haematopoietic cells following high-dose chemotherapy is
relatively well tolerated by patients, but entails a risk of
contamination. As a result, the complete remission rate is
relatively high but relapses are common. Our experience
in this respect is similar. In the group of patients who
underwent treatment, 12 (39%) achieved complete re-
mission and another 2 (6%) achieved partial remission.
The results are very close to 44% of CR reported by De-
sikan et al among 1000 patients with myeloma treated by
HCD/ASCT in one centre, similar results being repor-
ted by other groups [10-13]. Unfortunately, molecular
data indicates only sporadic occurrence of complete re-
mission following autologous transplantation [14, 15]. So-
me data suggest that a higher CR rate and prolonged
DFS and OS can be achieved by double transplants [16-
-18]. The issue of one versus two autotransplants for my-
eloma patients at diagnosis is currently being addressed in
two randomised studies [19, 20]. We have not observed
better survival in patients who received double transplan-
tation, but only seven patients were enrolled in the tan-
dem transplant program.
A large proportion of patients relapse after
HDC/ASCT. As a result 3 year EFS in our group is 31%.
Better EFS was observed in patients who received
HDC/ASCT as first line treatment than in patients with
advanced or resistant myeloma (p=0.015). Some authors
question the value of high-dose therapy in the treatment
of late myeloma [21]. Currently most centres perform
HDC/ASCT as a part of initial treatment [5-7, 16-19].
Only one early death observed among the 31 tre-
ated patients is a clear indication of minor risks associated
with transplantations. The only death was observed in
a patient with renal insufficiency. Renal failure is a well
established risk factor for HDC/ASCT [16]. In one study
transplant related mortality in such a group of patients
was as high as 29% [22]. Unfortunately, in cases treated
with standard therapy, median survival is around four
months and any attempt to overcome this would be more
than welcome [23]. Despite high transplant-related mor-
tality in some patients, stem cell transplantation contribu-
tes to the reversal of renal failure. In published studies al-
most half of the patients showed improvement in renal
functioning after HDC/ASCT [22, 24]. A query remains as
to what is the optimal conditioning regimen. Despite re-
sults of the study of Tricot et al. suggesting that high-dose
melphalan pharmacokinetics is not affected by renal func-
tioning, some authors prefer to use conditioning regi-
mens without melphalan [25, 26].
Figure 2. Overall survival of patients with multiple myeloma after au-
tologous haematopoietic cell transplantation
Figure 3. Disease free survival of patients with multiple myeloma after
autologous haematopoietic cell transplantation
Figure 4. Survival according to renal status at transplantation:
A-creatinine ≤ 2.0 mg/dl
B-creatinine > 2.0 mg/dl
Figure 5. Disease free survival according to time of transplantation
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Our results indicate that high-dose chemotherapy
followed by autologous transplantation of bone marrow is
a low risk procedure. It allows to achieve long term remis-
sion even in some patients suffering from an advanced
and treatment – resistant type of the disease. It must be
emphasised that autologous transplantation allows achie-
ving long term remission rather than complete elimination
of the disease. Nevertheless HDC/ASCT constitute pro-
gress in the treatment of patients with multiple myeloma.
Jaros∏aw Czy˝ M.D., Ph.D.
Department of Haematology
University Medical School of Gdaƒsk
D´binki 7, 81-211 Gdaƒsk
e-mail: jczyz@amg.gda.pl
References
1. Alexanian R, Bonnet J, Gehan E et al. Combination chemotherapy for
multiple myeloma. Cancer 1972; 30: 382-389.
2. Tsuchia J, Murakami H, Kanoh Ti et al. Ten-year survival and prognostic
factors in multiple myeloma. Br J Haemat 1994; 87: 832-834.
3. Kyle RA Long-term survival in multiple myeloma. N Engl J Med 1983; 10:
314-316.
4. Gregory WM, Richards MA, Malpas JS et al. Combination chemothera-
py versus melphalan and prednisolone in the treatment of multiple myelo-
ma. J Clin Oncol 1992; 10: 334-342.
5. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized
trial of autologous bone marrow transplantation and chemotherapy in
multiple myeloma. N Engl J Med 1996; 335: 91-97.
6. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autolo-
gous transplantation over standard therapy for previously untreated mul-
tiple myeloma. Blood 1997; 89: 789-793.
7. Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose
therapy with autologous stem cell support in patients younger than 60
years with newly diagnosed multiple myeloma: a population-based study.
Blood 2000; 95: 7-11.
8. Goldman JM, Schmitz N, Niethammer D, Gratwohl A. Indications for
stem cell transplantation” W: Apperly J, Gluckman E, Gratwohl A, Crad-
dock C (red.) The EBMT Handbook. Blood and Marrow Transplantation.
2000 Revised Edition. Paris: European School of Haematology; 2000,
56-68.
9. Blade J, Samson J, Reece D et al. Criteria for evaluating disease respon-
se and progression in patients with multiple myeloma treated by high-do-
se therapy and haemopoietic stem cell transplantation. Br J Haemat 1998;
102: 1115 -1123
10. Desikan R, Barlogie B, Sawyer J et al. Results of high-dose therapy for
1000 patients with multiple myeloma: durable complete remission and su-
perior survival rate in the absence of chromosom 13 abnormalities. Blood
2000; 95: 4008-4010.
11. Dimopoulos M, Alexanian R, Przepiorka D et al. Thiotepa, busulfan,
and cyclophosphamide: a new preparative regimen for autologous marrow
or blood stem cell transplantation in high-risk multiple myeloma. Blood
1993; 82: 2324-2328.
12. Harousseau JL, Attal M, Divine M et al. Autologous stem cell transplan-
tation after first remission induction treatment in multiple myeloma:
a report of the French Registry on Autologous Transplantation in Multi-
ple Myeloma. Blood 1995; 95: 3077-3085.
13. Bensinger WI, Rowley SD Demirer T et al. High-dose therapy followed by
autologous hematopoietic stem-cell infusion for patients with multiple my-
eloma. J Clin Oncol 1996; 14: 1447-1456.
14. Corradini P, Voena C, Astolfi M et al. High-dose sequential chemoradithe-
rapy in multiple myeloma: residual tumor cells are detectable in bone
marrow and peripheral blood cell harvests and after autografting. Blood
1995; 85: 1596-1602.
15. Corradini P, Voena C, Tarella C et al. Molecular and clinical remission in
multiple myeloma: role of autologous and allogenic transplantation of he-
matopoietic cells. J Clin Oncol 1999; 17: 208-215.
16. Vesole HV, Tricot G, Jagannath S et al. Autotransplants in multiple myelo-
ma:what have we learned? Blood 1996; 88: 838-842.
17. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem
transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
18. Lemoli RM, Martinelli GM, Zamagni E et al. Engraftment, clinical, and
molecular follow-up of patients with multiple myeloma who were reinfu-
sed with highly purfired CD34+ cells to support single or tandem high-do-
se chemotherapy. Blood 2000; 95: 2234-2239.
19. Attal M., Payen C, Facon T et al. Single versus double transplant in myelo-
ma: a randomized trial of the 'Inter Groupe Francais du Myelome'. [abs-
tract] Bone Marrow Transplant 1998; 21: S206.
20. Tosi P, Cavo M, Zamagni E et al. A multicentric randomised trial compa-
ring single vs double autologous peripheral blood stem cell transplantation
for patients with newly diagnosed multiple myeloma: results of interim
analysis. [abstract] Blood 1999; 94:715a.
21. Alexanian R, Dimopoulos M, Smith T et al. Limited value of myeloabla-
tive therapy for late multiple myeloma. Blood 1994; 83: 512-516.
22. San Miguel JF, Lahuerta JJ, Garcia-Sanz R et al. Are myeloma patients
with renal failure candidates for autologous stem cell transplantation? The
Hematology Journal 2000; 1: 28-36.
23. Blade J, Fernandez-Lama P, Bosch F et al. Renal failure in multiple my-
eloma. Archives of Internal Medicine 1998; 158: 1889-1893.
24. Tosi P, Zamagni E, Rouconi S et al. Safety of autologous hematopoietic
stem cell transplantation in patients with multiple myeloma and chronic
renal failure. Leukemia 2000; 14: 1310 – 1313
25. Ballester OF, Tummala R, Janssen WE et al. High-dose chemotherapy
and autologous peripheral blood stem cell transplantation in patients
with multiple myeloma and renal insufficiency. Bone Marrow Transplanta-
tion 1997; 20: 653-656.
26. Tricot G, Alberts DS., Johnson CH et al. Safety of autotransplants with
high-dose melphalan in renal failure: a pharmacokinetic and toxicity stu-
dy. Clinical Cancer Research 1996; 2: 947-952.
Paper received: 27 December 2001
Accepted: 28 March 2002
